Ananda Pharma Plc (ANA) RNS Announcements

Add to Alert list
Date Time Source Announcement
15 Jul 2025 09:31 AM
RNS
First Participant Dosed in MRX1 CBD Phase 1 Study
01 Jul 2025 07:00 AM
RNS
MRX1 Delivered to Clinical Trial Site
23 Jun 2025 07:00 AM
RNS
Key Milestone in MRX1 Path to Clinical Trials
03 Jun 2025 07:00 AM
RNS
Publication of Phase 1 study on clinicaltrials.gov
02 Jun 2025 07:00 AM
RNS
MRX1 achieves 2 years of stability data
27 May 2025 07:00 AM
RNS
Ananda to attend Benzinga Conference
06 May 2025 07:00 AM
RNS
Appointment of Giles Moss as Advisor
28 Apr 2025 07:00 AM
RNS
TGA Receives Ananda’s Clinical Trial Notification
14 Apr 2025 07:00 AM
RNS
Ananda Pharma commences trading on OTCQB Exchange
08 Apr 2025 07:00 AM
RNS
Appointment of Chris Tovey, GW Pharma Former COO
02 Apr 2025 07:00 AM
RNS
MRX1 Granted Ethics Approval for Phase 1 Study
12 Mar 2025 07:00 AM
RNS
Master Investor Conference Attendance
04 Mar 2025 07:00 AM
RNS
Director/PDMR Shareholding
21 Feb 2025 07:00 AM
RNS
CEO Presenting at Private Investor Conference
20 Feb 2025 07:00 AM
RNS
Achievement of Manufacturing Milestone for MRX1
06 Feb 2025 03:06 PM
RNS
Director/PDMR Shareholding
06 Feb 2025 07:00 AM
RNS
Appointment of Commercial Adviser
03 Feb 2025 04:35 PM
RNS
Change of Registered Office
03 Feb 2025 07:00 AM
RNS
Ananda Pharma Appoints Viridian Capital Advisors
22 Jan 2025 07:00 AM
RNS
2025 Kick-Off Webinar
07 Jan 2025 11:34 AM
RNS
Total Voting Rights
20 Dec 2024 07:00 AM
RNS
Change of Name
11 Dec 2024 07:00 AM
RNS
Subscription to raise £150,000
09 Dec 2024 07:00 AM
RNS
Further Promising Results for MRX1
03 Dec 2024 07:00 AM
RNS
Key Stability Testing Milestones Achieved for MRX1
25 Nov 2024 12:00 PM
RNS
Publication of article in Leading Journal
12 Nov 2024 07:00 AM
RNS
Director Dealing
04 Nov 2024 07:00 AM
RNS
Presenting at Aquis Showcase
31 Oct 2024 07:00 AM
RNS
Total Voting Rights
30 Oct 2024 07:30 AM
RNS
Investor Meet Company Presentation
30 Oct 2024 07:00 AM
RNS
Interims for the six months ended 31 July 2024
21 Oct 2024 07:00 AM
RNS
Ananda Developments Epilepsy Trials
09 Oct 2024 07:00 AM
RNS
Phase 1 PK Study to be conducted on MRX1
08 Oct 2024 02:45 PM
RNS
Result of General Meeting
08 Oct 2024 10:50 AM
RNS
Change of Location for General Meeting
07 Oct 2024 07:00 AM
RNS
Addition to Scientific Advisory Board
30 Sep 2024 07:00 AM
RNS
Total Voting Rights
19 Sep 2024 07:00 AM
RNS
Notice of General Meeting
16 Sep 2024 07:00 AM
RNS
Result of WRAP Retail Offer
09 Sep 2024 11:30 AM
RNS
WRAP Retail Offer for up to £100,000
09 Sep 2024 10:30 AM
RNS
Placing and Subscription to raise c.£2.15 million
29 Aug 2024 08:00 AM
RNS
Launch of CBD Whitepaper
29 Aug 2024 07:00 AM
RNS
Management accounts for quarter ended 31 July 2024
09 Aug 2024 10:56 AM
RNS
Result of AGM
05 Aug 2024 07:00 AM
RNS
Graduation to Apex segment of AQSE Growth Market
16 Jul 2024 07:00 AM
RNS
Notice of AGM
15 Jul 2024 07:00 AM
RNS
Publication of Annual Report and Accounts
11 Jul 2024 07:00 AM
RNS
Invitation to Investor Evening
26 Jun 2024 07:00 AM
RNS
Promising Results from Cardiac Fibrosis Studies
11 Jun 2024 01:27 PM
RNS
Extension of Mark Ling as Senior Statutory Auditor
UK 100